NVO vs NVS
NVO: A leading global healthcare company focused on conquering chronic diseases, particularly diabetes and cardiovascular conditions. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | NVO | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $47.08 | $156.11 | |
| Market cap as of 2026-08-03 | $223.4B | $232.1B | |
| P/E as of 2026-08-03 | 12.03 | 22.53 | NVO lower |
| PEG as of 2026-08-03 | 16.16 | 3.66 | NVS lower |
| Net margin as of 2026-08-03 | +37.2% | +22.5% | NVO higher |
| Gross margin as of 2026-08-03 | +81.8% | +75.0% | NVO higher |
| Operating margin as of 2026-08-03 | +45.3% | +29.9% | NVO higher |
| ROE as of 2026-08-03 | +66.4% | +29.9% | NVO higher |
| ROA as of 2026-08-03 | +23.3% | +11.1% | NVO higher |
| Debt / equity as of 2026-08-03 | 0.72 | 1.18 | NVO lower |
| Revenue growth (YoY) as of 2026-08-03 | +8.1% | +3.3% | NVO higher |
| Revenue CAGR (3y) SEC XBRL | +20.4% | n/a | |
| Dividend yield as of 2026-08-03 | +3.8% | +2.9% | NVO higher |
| Beta as of 2026-08-03 | 0.89 | 1.17 | |
| 1-year return as of 2026-07-31 close | +0.0% | +32.6% | NVS higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.